Patient compliance has long been a problem associated with treatment of wet type age-related macular degeneration (AMD). Current treatment is simply not very pleasant and may require many painful injections over six months. A longtime goal among pharmaceutical companies is to develop something easier for drug delivery to the back of the eye. The University of Texas at Austin is licensing what it says is a unique solution for wet type AMD drug delivery. The treatment involves a one-time implantation of a carrier system for the drug. Then, each time the patient needs medication, the doctor can operate a laser beam to release it in measurable doses. More